A Study of Teduglutide in Japanese People With Short Bowel Syndrome

Short Bowel Syndrome Clinical Trial

Official title:

Special Drug Use Investigation of Revestive Subcutaneous Injection 3.8 mg (All-case Surveillance)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05023382
• Other study ID #: TAK-633-5001
• Status: Recruiting
• Start date: September 1, 2021
• Est. completion date: July 31, 2030

Study information

• Verified date: October 2023
• Source: Takeda
• Contact: Takeda Contact
• Phone: +1-877-825-3327
• Email: medinfoUS[@]takeda.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main aims of this study are to check for side effects from treatment with teduglutide (Revestive) and how well teduglutide controls symptoms of short bowel syndrome. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. During the study, participants with short bowel syndrome will receive an injection of teduglutide just under the skin (subcutaneous) according to their clinic's standard practice. The study doctors will check for side effects from teduglutide for 36 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: July 31, 2030
• Est. primary completion date: July 31, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All participants in Japan who received teduglutide will be enrolled in this post marketing surveillance.

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Short Bowel Syndrome
• Syndrome

Intervention

Drug:
• Teduglutide
Teduglutide 0.05 mg/kg SC injection

Locations

Country	Name	City	State
Japan	Takeda Selected Site	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Adverse Events	An adverse event (AE) is any untoward or undesirable medical occurrence in a participant linked in time with the use of a pharmaceutical/ medicinal product. They are not limited to the events with clear causal relationship with treatment with concerned drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.	Up to 36 months
Primary	Number of Participants with Serious Adverse Events	A serious AE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability /incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.	Up to 36 months
Secondary	Changes from Baseline in Prescription Volume of Parenteral Nutrition Intravenous (PN/IV) Support	Changes from baseline in prescription volume of PN/IV support prescribed by investigators to 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation will be reported.	Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
Secondary	Percent Change from Baseline in Prescription Volume of PN/IV Support	Percent change from baseline in prescription volume of PN/IV support to multiple timepoints (6, 12, 18, 24, 30, and 36 months) after teduglutide treatment initiation will be reported. Percent change from baseline will be calculated as following; [prescription volume at each timepoint - prescription volume at baseline] / prescription volume at baseline * 100 (percent).	Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
Secondary	Changes from Baseline in Dose of PN/IV Support	Changes from baseline in actual dose of PN/IV support to 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation will be reported.	Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
Secondary	Percent Change from Baseline of Dose in PN/IV Support	Percent change from baseline in actual dose of PN/IV support to multiple timepoints (6, 12, 18, 24, 30, and 36 months) after teduglutide treatment initiation will be reported. Percent change from baseline will be calculated as following; [actual dose at each timepoint - actual dose at baseline] / actual dose at baseline * 100 (percent).	Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
Secondary	Percentage of Participants who Completely Wean off PN/IV Support	Number of participants who completely wean off PN/IV support will be assessed.	Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation
Secondary	Crohn's Disease Activity Index (CDAI)	CDAI score is calculated from the following 8 items: (a) Number of liquid or very soft stools; (b) Abdominal pain; (c) General wellbeing; (d) Extraintestinal complications; (e) Antidiarrhoeal drugs; (f) Abdominal mass; (g) Hematocrit; and (h) Body weight. Scores of some items in CDAI are calculated based on patient diary. Total range of score is more than 0. Higher score means more severe disease and especially severe disease was defined as a value of greater than 450.	36 months after teduglutide treatment initiation